Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”
Grabbed $3.50’s..should find out who they partnered with..soon enough
Up 12% 2nd million..let’s see 3rd
Yall musta seen 911 trade..bout40min before $3.80’s breakout l..yesterday
“Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference”
$5 would be nice
Inherent risk in industry..temporary
THIS POS IS LOSING AN ENORMOUS AMOUNT OF MONEY.IT SHOULD BE TRADING IN THE .30 AREA.MAX.
Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022.
•
Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
•
Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022. The $1.8 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors.
•
General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022. The decrease was primarily due to a decrease in consulting and professional expenses and personnel costs.
Year-to-Date
•
Net cash used in operations for the nine months ended September 30, 2023 was $21.2 million.
•
Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
Research and development expenses for the nine months ended September 30, 2023 were $13.3 million compared to $16.7 million for the same period in 2022. The $3.4 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors, partially offset by an increase in facilities expenses.
•
General and administrative expenses for the nine months ended September 30, 2023 were $8.3 million compared to $9.0 million for the same period in 2022. The $0.7 million decrease was primarily due to a decrease in consulting and professional expenses.
Nice premarket movement on earnings report..no chart signal lmao.
“Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update”
This is scam !! stay away, most phase 2 pumps are scams
They fail in phase 3
Yeah but what a pump. From .17 to 9.77 in one day!!! Just had to be lucky that day.
Nope, anytime before the 14th
Earnings come out Tuesday?
That’s just dumb say trader verbiage..no actual knives falling..lol
what a big bag holder u are!!!!! don't catch falling knife
On the way to 0.75 - get out while you can
PUMP n DUMP games !!! almost all biotech stocks are P&D games - Huge pumps and thend umps back to where they were
Look at Moderna and NVAX after convid dump - Yikes
Both are down 80%
Nvax is down 95%
lol
TPST$$$$$
EXPLOSION COMING SOON....
and again your still here get a life dude
This is heading to 0.75 !! It was pump n dump game
Yep nice finish
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
554
|
Created
|
04/04/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |